Summarized by Masters of Longevity from PR Newswire.
Clinical data report shows a transformer Base Editor therapy delivers consistent, durable remission in diverse β-hemoglobinopathy patients by reactivating fetal hemoglobin expression.
Key Takeaways
- A tBE-based therapy produced rapid neutrophil and platelet engraftment within about two to four weeks post-infusion in treated patients.
- Treated patients achieved sustained high HbF levels and either complete transfusion independence or freedom from vaso-occlusive crises for over a year.
- No detectable off-target edits or product-related adverse events were reported across more than 30 patients treated across multiple regions.
